Pioglitazone
Small molecule targets PPARG via activation
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (5) | US (FDA) | ACTOS | — | 2002-07-12 – 2016-12-12 | fda.gov ↗ |
| Approved | EU (EMA) | Glustin | — | 2000-10-11 | europa.eu ↗ |
| Approved | US (FDA) | ACTOS | — | 1999-07-15 | fda.gov ↗ |
Trials 290 · started per year
Also used as a comparator or background therapy in 204 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT03866408 Comparator | Nov 2018 → Dec 2026 expected | obesity disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 0 | NCT02689843 Comparator | Feb → Nov 2018 | polycystic ovary syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03566225 Comparator | Jan 2018 → Feb 2021 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT03117517 Comparator | Mar → Aug 2017 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 0 | NCT02919176 Comparator | Sep 2016 → Feb 2019 | metabolic syndrome X, obesity disorder | Philip Kern | Completed | No outcome recorded |
| Phase 0 | NCT02341703 Comparator | Feb → Jul 2015 | infertility disorder, polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT01909141 Comparator | Aug 2013 → Feb 2014 | infertility disorder, polycystic ovary syndrome | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT00720577 Comparator | Dec 2005 → Jul 2007 | peripheral arterial disease | Medtronic Endovascular | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT07053319 Comparator | May 2026 → Jun 2027 expected | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 1 | NCT03298464 Comparator | Sep 2017 → Jun 2018 | obesity disorder | NGM Biopharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02535832 Comparator | Sep 2015 → Oct 2022 | rheumatoid arthritis | Ohio State University | Completed | No outcome recorded |
| Phase 1 | NCT01115712 Comparator | May → Sep 2010 | obesity disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02183636 Comparator | Aug → Dec 2009 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00719381 Comparator | Jan 2008 → Jun 2009 | cystic fibrosis | Paul Beringer | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT01010243 Background | Oct 2009 → Oct 2013 | plasma cell myeloma | University of Regensburg | Unknown | No outcome recorded |
| Phase 1/2 | NCT00919555 Comparator | Jun 2008 → Nov 2009 | amyotrophic lateral sclerosis | Phoenix Neurological Associates, LTD | Completed | No outcome recorded |
| Phase 1/2 | NCT01396564 Comparator | Oct 2005 → Oct 2006 | type 2 diabetes mellitus | Coordinación de Investigación en Salud, Mexico | Completed | No outcome recorded |
| Phase 1/2 | NCT02503865 Comparator | Jan 2003 → Dec 2008 | metabolic syndrome X | Nazarbayev University | Completed | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT05254626 Comparator | Aug 2022 → Jan 2024 | metabolic dysfunction-associated steatohepatitis | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT05013255 Comparator | Dec 2021 → Dec 2026 expected | breast cancer | West Virginia University | Recruiting | No outcome recorded |
| Phase 2 | NCT04843046 Comparator | Aug 2021 → Sep 2025 | substance-related disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 2 | NCT04662866 Comparator | Feb 2021 → Dec 2022 | glucose intolerance | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04501406 Comparator | Dec 2020 → Aug 2027 expected | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | University of Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT04113889 Comparator | Oct 2019 → Jan 2020 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT04883125 Comparator | Jan 2018 → Apr 2021 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT02697617 Comparator | Jan 2016 → Oct 2019 | polycystic kidney disease | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT02303405 Comparator | Nov 2014 → Nov 2017 | type 2 diabetes mellitus | Charles Drew University of Medicine and Science | Terminated | No outcome recorded |
| Phase 2 | NCT02278562 Comparator | Oct 2014 → Mar 2017 | end stage renal failure | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2 | NCT02195791 Comparator | Jul 2014 → Aug 2016 | stroke disorder | Taipei Medical University Shuang Ho Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01280695 Comparator | Feb → Jun 2011 | type 2 diabetes mellitus | Metabolic Solutions Development Company | Completed | No outcome recorded |
| Phase 2 | NCT01230749 Comparator | Dec 2010 → Jun 2011 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT01217073 Comparator | Oct 2010 → Jan 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01103414 Comparator | Sep 2010 → Nov 2011 | type 2 diabetes mellitus | Metabolic Solutions Development Company | Completed | No outcome recorded |
| Phase 2 | NCT01186250 Comparator | Jul 2010 → Aug 2013 | — | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT01043029 Comparator | May 2010 → Jul 2012 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01028963 Comparator | Jan → Oct 2010 | type 2 diabetes mellitus | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00634036 Comparator | Oct 2009 → Apr 2012 | asthma | Fernando Holguin | Completed | No outcome recorded |
| Phase 2 | NCT00787644 Comparator | Jan 2009 → Jun 2013 | asthma, obesity disorder | University of Vermont | Terminated | No outcome recorded |
| Phase 2 | NCT00814372 Comparator | Dec 2008 → Feb 2010 | type 2 diabetes mellitus | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT00782795 Comparator | Nov 2008 → Dec 2013 | chronic pancreatitis | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT00760578 Comparator | Sep 2008 → Jan 2009 | type 2 diabetes mellitus | Metabolic Solutions Development Company | Completed | No outcome recorded |
| Phase 2 | NCT00825266 Comparator | Sep 2008 → May 2010 | pulmonary arterial hypertension | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT00722917 Comparator | Jul 2008 → Apr 2009 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 2 | NCT00690118 Comparator | May 2008 → Jun 2010 | amyotrophic lateral sclerosis | University of Ulm | Terminated | No outcome recorded |
| Phase 2 | NCT00631007 Comparator | Feb 2008 → Aug 2009 | type 2 diabetes mellitus | InteKrin Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00575874 Comparator | Aug 2007 → Jun 2008 | type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00461006 Comparator | Jun 2007 → Sep 2008 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00461058 Comparator | May → Dec 2007 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00427999 Background | Feb 2007 → Jun 2015 | prostate cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00388518 Comparator | Nov 2006 → Mar 2008 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00543959 Comparator | Jun 2006 → Aug 2007 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00368017 Comparator | Apr 2006 → Sep 2007 | chronic kidney disease | Vanderbilt University | Terminated | No outcome recorded |
| Phase 2 | NCT00290940 Background | Jan 2006 → Apr 2007 | type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 2 | NCT00443755 Comparator | Aug 2005 → Aug 2010 | metabolic syndrome X, type 2 diabetes mellitus | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00481663 Background | Aug 2003 → Jul 2004 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT01109030 Comparator | Apr 2010 → Oct 2011 | major depressive disorder | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01318122 Comparator | May 2008 → Aug 2009 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2/3 | NCT01318070 Comparator | Nov 2007 → Oct 2008 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2/3 | NCT00353587 Comparator | May 2006 → Nov 2007 | type 2 diabetes mellitus | Gilead Sciences | Completed | No outcome recorded |
| Phase 364 trials | ||||||
| Phase 3 | NCT05028140 Comparator | Oct 2024 → Jul 2026 overdue | type 2 diabetes mellitus | EMS | Recruiting | No outcome recorded |
| Phase 3 | NCT06571591 Comparator | Aug 2024 → Apr 2026 | type 2 diabetes mellitus | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT06107153 Comparator | Nov 2023 → Nov 2024 | type 2 diabetes mellitus | University of Basrah | Completed | No outcome recorded |
| Phase 3 | NCT05591235 Comparator | Nov → Dec 2022 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT05605158 Comparator | Nov 2022 → May 2023 | metabolic dysfunction-associated steatohepatitis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05629806 Comparator | Apr 2022 → May 2023 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT05098327 Comparator | Aug 2021 → Mar 2023 | hypogonadism, male, prostate cancer, type 2 diabetes mellitus | State University of New York at Buffalo | Withdrawn | No outcome recorded |
| Phase 3 | NCT05521633 Comparator | Jun 2019 → Jan 2021 | fatty liver disease | King Edward Medical University | Completed | No outcome recorded |
| Phase 3 | NCT02787551 Background | Jul 2016 → May 2018 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03125694 Comparator | Feb 2015 → Apr 2017 | type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02265276 Comparator | Oct 2014 → Sep 2015 | fatty liver disease | Command Hospital, India | Unknown | No outcome recorded |
| Phase 3 | NCT01894568 Background | Jul 2013 → Apr 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01289119 Background | Dec 2010 → Dec 2011 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01225081 Background | Sep 2010 → Apr 2012 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT01183013 Comparator | Aug 2010 → Feb 2013 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01106690 Background | Jun 2010 → Nov 2011 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01095666 Background | Jun 2010 → Mar 2013 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01106131 Comparator | May 2010 → Apr 2012 | type 2 diabetes mellitus | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01064687 Background | Feb 2010 → Nov 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00927290 Comparator | Dec 2009 → Jul 2012 | chronic hepatitis C virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
| Phase 3 | NCT01026194 Background | Dec 2009 → Jun 2011 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00975286 Background | Oct 2009 → Aug 2011 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00909597 Comparator | May 2009 → Nov 2010 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00885352 Background | Apr 2009 → Nov 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00789750 Background | Apr 2009 → Jul 2012 | type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00839527 Comparator | Feb 2009 → Jan 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00676338 Comparator | Nov 2008 → Jul 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00408850 Comparator | Nov 2008 → Feb 2013 | metabolic syndrome X | Baker Heart Research Institute | Unknown | No outcome recorded |
| Phase 3 | NCT00744367 Background | Oct 2008 → Nov 2010 | type 2 diabetes mellitus | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00763815 Background | Sep 2008 → Jun 2011 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00736099 Background | Aug 2008 → Dec 2010 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00376870 Comparator | Jul 2008 → Dec 2010 | coronary atherosclerosis, coronary restenosis, diabetes mellitus | University of Rome Tor Vergata | Unknown | No outcome recorded |
| Phase 3 | NCT00683878 Background | Jul 2008 → Jan 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00680745 Background | Apr 2008 → Nov 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01156597 Comparator | Apr 2008 → Sep 2010 | type 2 diabetes mellitus | University of Miami | Completed | No outcome recorded |
| Phase 3 | NCT00641043 Background | Mar 2008 → Jun 2009 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00532935 Comparator | Jan 2008 → Oct 2009 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00541450 Comparator | Jan 2008 → Jan 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00637273 Comparator | Jan 2008 → Feb 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00571519 Comparator | Nov 2007 → May 2008 | type 2 diabetes mellitus | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 3 | NCT00727857 Comparator | Jun 2007 → Aug 2008 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00484198 Comparator | Apr 2007 → Feb 2009 | type 2 diabetes mellitus | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 3 | NCT00328393 Comparator | Mar 2007 | hypertensive disorder, type 2 diabetes mellitus | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00397631 Comparator | Dec 2006 → Jun 2008 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00396227 Comparator | Oct 2006 → Oct 2007 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00372060 Background | Aug 2006 → Feb 2008 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00376181 Comparator | Jun 2006 → May 2007 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00327015 Background | May 2006 → Nov 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00295633 Background | Mar 2006 → Oct 2007 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00286494 Background | Feb 2006 → Aug 2007 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00121667 Background | Aug 2005 → Oct 2006 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00106704 Comparator | Mar 2005 → Jun 2006 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00091949 Comparator | Feb 2005 → Nov 2015 | diabetes mellitus, myocardial infarction, stroke disorder | Yale University | Completed | No outcome recorded |
| Phase 3 | NCT00063622 Comparator | Jan 2005 → Jun 2009 | liver disorder | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 3 | NCT00138554 Background | Nov 2004 → Jul 2006 | type 2 diabetes mellitus | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00094757 Comparator | Oct 2004 → Aug 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00097279 Background | Aug 2004 → Aug 2005 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00086515 Background | Jun 2004 → Jul 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00086502 Comparator | Jun 2004 → Nov 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00099853 Background | May 2004 → Jan 2008 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00220961 Comparator | Jan 2004 → Apr 2010 | glucose intolerance, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 3 | NCT00324350 Comparator | Oct 2003 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00598793 Background | Nov 2002 → Mar 2004 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 459 trials | ||||||
| Phase 4 | NCT07289750 Comparator | May 2026 → Aug 2027 expected | metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07462065 Comparator | Mar → Jun 2026 overdue | female infertility | PAEC General Hospital, Islamabad | Recruiting | No outcome recorded |
| Phase 4 | NCT07180745 Comparator | Nov 2025 → Feb 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Badr University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06922656 Comparator | Sep 2025 → Sep 2026 expected | type 1 diabetes mellitus | Dasman Diabetes Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06243536 Comparator | Feb → Dec 2024 | eating disorder, obesity disorder, type 2 diabetes mellitus | University Hospital Sestre Milosrdnice | Unknown | No outcome recorded |
| Phase 4 | NCT06399835 Comparator | Feb 2024 → Dec 2026 expected | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05838287 Comparator | Jul 2023 → Aug 2029 expected | heart failure, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 4 | NCT05775380 Comparator | Jun 2023 → Jun 2024 | myocardial infarction | University of Campinas, Brazil | Unknown | No outcome recorded |
| Phase 4 | NCT05813249 Comparator | Feb 2023 → Feb 2024 | NAFLD1 | Zagazig University | Completed | No outcome recorded |
| Phase 4 | NCT04976283 Comparator | Sep 2021 → May 2023 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Getz Pharma | Unknown | No outcome recorded |
| Phase 4 | NCT04657939 Comparator | Dec 2020 → Oct 2022 | type 2 diabetes mellitus | University of Leeds | Completed | No outcome recorded |
| Phase 4 | NCT04392557 Comparator | Jul → Sep 2020 | type 2 diabetes mellitus | University of Catanzaro | Unknown | No outcome recorded |
| Phase 4 | NCT03910361 Comparator | Apr 2019 → Jul 2020 | NAFLD1, type 2 diabetes mellitus | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03471117 Comparator | Apr 2018 → Apr 2026 overdue | chronic kidney disease | The University of Texas at Arlington | Recruiting | No outcome recorded |
| Phase 4 | NCT03196362 Comparator | Dec 2016 → Sep 2018 | type 2 diabetes mellitus | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT02616666 Comparator | Aug 2016 → Dec 2025 | type 2 diabetes mellitus | University of Liverpool | Completed | No outcome recorded |
| Phase 4 | NCT02694263 Comparator | Jul 2016 → Sep 2018 | type 2 diabetes mellitus | University of Leicester | Completed | No outcome recorded |
| Phase 4 | NCT02875821 Comparator | Apr 2016 → Jun 2017 | NAFLD1 | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT04470310 Comparator | Dec 2015 → May 2019 | type 2 diabetes mellitus | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02315287 Comparator | Sep 2014 → Dec 2021 | type 2 diabetes mellitus | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02231021 Comparator | Sep 2014 → Oct 2018 | type 2 diabetes mellitus | Kun-Ho Yoon | Completed | No outcome recorded |
| Phase 4 | NCT01919489 Comparator | Mar 2014 → Aug 2020 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02072096 Background | Feb 2014 → Oct 2015 | type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 4 | NCT02365233 Comparator | May 2013 → Dec 2016 | NAFLD1, type 2 diabetes mellitus | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 4 | NCT01559857 Comparator | Nov 2011 → Jan 2014 | major depressive disorder | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT01471808 Comparator | Oct 2011 → Dec 2018 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 4 | NCT02292290 Comparator | Apr 2011 → Dec 2012 | type 2 diabetes mellitus | University of Leicester | Completed | No outcome recorded |
| Phase 4 | NCT01087567 Comparator | Jul 2010 → Jan 2014 | type 2 diabetes mellitus | Ohio University | Completed | No outcome recorded |
| Phase 4 | NCT01002547 Comparator | Jun 2010 → Sep 2016 | metabolic dysfunction-associated steatohepatitis | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT01339143 Comparator | Apr 2010 → Dec 2012 | type 2 diabetes mellitus | Korea University Anam Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01882907 Comparator | Dec 2009 → Mar 2013 | type 2 diabetes mellitus | Pusan National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01195090 Comparator | Oct 2009 → Oct 2011 | type 2 diabetes mellitus | Sung-Chen Liu | Completed | No outcome recorded |
| Phase 4 | NCT01223196 Comparator | Aug 2009 → Dec 2011 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT00879970 Comparator | May 2009 → Nov 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 4 | NCT00780715 Comparator | Dec 2008 → Oct 2009 | type 2 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT00994682 Comparator | Dec 2008 → Dec 2014 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT00656864 Comparator | May 2008 → Nov 2010 | type 2 diabetes mellitus | University of Vermont | Completed | No outcome recorded |
| Phase 4 | NCT00437970 Comparator | Apr 2008 → Jan 2009 | type 2 diabetes mellitus | Menzies School of Health Research | Withdrawn | No outcome recorded |
| Phase 4 | NCT00485056 Comparator | Apr 2008 → Apr 2010 | diabetes mellitus | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT00953498 Comparator | Oct 2007 → Mar 2012 | type 2 diabetes mellitus | Centre Hospitalier Universitaire Dijon | Completed | No outcome recorded |
| Phase 4 | NCT00845182 Comparator | Jun 2007 → Jul 2010 | glucose intolerance, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT01253928 Comparator | Mar 2007 → Jun 2011 | end stage renal failure | Centre Hospitalier Universitaire Vaudois | Unknown | No outcome recorded |
| Phase 4 | NCT01322308 Comparator | Mar 2007 → Jan 2012 | systemic lupus erythematosus | National Heart Institute, Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00926341 Comparator | Oct 2006 → Jun 2008 | metabolic syndrome X | Aligarh Muslim University | Completed | No outcome recorded |
| Phase 4 | NCT00315146 Comparator | Apr 2006 → Apr 2007 | morbid obesity | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01090752 Comparator | Oct 2005 → Oct 2007 | diabetes mellitus, hypertensive disorder | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 4 | NCT00231894 Comparator | May 2005 → Jan 2010 | diabetes mellitus, schizophrenia | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
| Phase 4 | NCT00212004 Comparator | Apr 2005 → Apr 2017 | myocardial infarction, type 2 diabetes mellitus | National Cerebral and Cardiovascular Center, Japan | Terminated | No outcome recorded |
| Phase 4 | NCT00579813 Comparator | Apr 2005 → Jan 2009 | metabolic syndrome X, prediabetes syndrome | Philip Kern | Completed | No outcome recorded |
| Phase 4 | NCT00576784 Comparator | Apr 2005 → Apr 2007 | type 2 diabetes mellitus | IKFE Institute for Clinical Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT00189163 Comparator | Jan 2005 → Dec 2007 | chronic hepatitis C virus infection | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT00570622 Comparator | Dec 2004 → Nov 2008 | cirrhosis of liver, portal hypertension | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00571506 Comparator | May 2004 → Aug 2007 | type 2 diabetes mellitus, vascular disorder | University of Arkansas | Completed | No outcome recorded |
| Phase 4 | NCT00609856 Comparator | Apr 2004 → Dec 2006 | idiopathic steroid-sensitive nephrotic syndrome with secondary steroid resistance, type 2 diabetes mellitus | Skane University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00108615 Comparator | Jan 2004 → Apr 2007 | diabetes mellitus | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00227110 Comparator | Oct 2002 → Nov 2005 | metabolic dysfunction-associated steatohepatitis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT01799850 Comparator | Mar 2002 → Mar 2004 | type 2 diabetes mellitus | East Tennessee State University | Completed | No outcome recorded |
| Phase 4 | NCT00179400 Comparator | Dec 2000 → Jul 2011 | type 2 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase not applicable22 trials | ||||||
| — | NCT07391267 Background | Feb 2026 → Dec 2028 expected | chronic kidney disease, metabolic dysfunction-associated steatotic liver disease | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT05501483 Comparator | Feb 2023 → Sep 2026 expected | type 2 diabetes mellitus | Karolinska Institutet | Recruiting | No outcome recorded |
| — | NCT05422092 Comparator | Sep 2022 → Jan 2023 | type 2 diabetes mellitus | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT02879409 Background | Nov 2016 → Oct 2023 overdue | type 2 diabetes mellitus | Weill Cornell Medical College in Qatar | Active not recruiting | No outcome recorded |
| — | NCT02969798 Comparator | Jan 2014 → Dec 2026 expected | glucose intolerance, prediabetes syndrome, type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| — | NCT01963663 Comparator | Nov 2012 → Mar 2013 | type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01819402 Comparator | Mar 2012 → Apr 2013 | — | Kurume University | Unknown | No outcome recorded |
| — | NCT02027103 Comparator | Jan → Mar 2012 | type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01593371 Comparator | Jul → Oct 2011 | type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01748994 Comparator | Feb 2011 → Dec 2016 | metabolic syndrome X, obesity disorder | Pennington Biomedical Research Center | Completed | No outcome recorded |
| — | NCT02192684 Comparator | Sep 2010 → Jul 2014 | obstructive sleep apnea syndrome | Stanford University | Completed | No outcome recorded |
| — | NCT01147627 Comparator | Aug 2010 → Aug 2012 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT01133561 Comparator | Jan → Jul 2010 | psoriasis | Cairo University | Completed | No outcome recorded |
| — | NCT00927355 Comparator | Apr 2009 → Oct 2010 | — | Emory University | Completed | No outcome recorded |
| — | NCT00843791 Comparator | Feb 2009 → May 2011 | obesity disorder | Oregon Health and Science University | Terminated | No outcome recorded |
| — | NCT01301027 Comparator | May 2008 → Dec 2015 | end stage renal failure | University of Utah | Completed | No outcome recorded |
| — | NCT00694759 Comparator | Oct 2006 → Jun 2011 | polycystic ovary syndrome | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT00926016 Comparator | Jun 2006 → Mar 2010 | chronic hepatitis C virus infection | Brooke Army Medical Center | Completed | No outcome recorded |
| — | NCT00586261 Comparator | Mar 2006 → Jan 2009 | chronic kidney disease | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT00656851 Comparator | Sep 2005 → Aug 2009 | HIV infectious disease, cardiovascular disorder, lipodystrophy, metabolic syndrome X | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| — | NCT00232583 Comparator | Nov 2003 → Dec 2011 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT01570660 Comparator | Feb 2002 → Mar 2012 | type 2 diabetes mellitus | German Diabetes Center | Completed | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-12-16 | Takeda | Benefit/Risk Profile Remains Positive for Pioglitazone as an Important Treatment Option for Type 2 Diabetes takeda.com ↗ |
| 2015-09-12 | Takeda | More than 96 Percent of Claimants Opt-In to ACTOS Resolution Program; Takeda Expects Resolution to Become Effective Once Submission Review Completed; Takeda Stands Behind ACTOS takeda.com ↗ |
| 2015-07-31 | Takeda | Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA takeda.com ↗ |
| 2015-04-29 | Takeda | Takeda Agrees to Settle ACTOS Product Liability Lawsuits and Claims; Takeda Stresses Continued Commitment to ACTOS takeda.com ↗ |
| 2014-08-29 | Takeda | Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS takeda.com ↗ |
| 2014-05-23 | Takeda | Jury Finds for Takeda in Diabetes Drug Case Takeda Stresses Continued Confidence in Actos takeda.com ↗ |
| 2014-05-16 | Takeda | Jury Finds for Takeda in Diabetes Drug Case Takeda Emphasizes Continued Commitment to Actos and Patient Safety takeda.com ↗ |
| 2012-08-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Actos® in the United States tevapharm.com ↗ |
| 2010-12-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Takeda Settle Generic ACTOS® and ACTOplus met® Litigation tevapharm.com ↗ |
Evidence & citations 44 cited values
Every value below carries the sentence it was read from. 502 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pioglitazone | “BACKGROUND AND OBJECTIVES: To establish pharmacokinetic bioequivalence and assess the safety of a single-dose administration of fixed-dose combination (FDC) tablet containing...” PMID 42270920 ↗ Jun 2026483“Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7%...” NCT04013581 ↗ “The Effect of Alogliptin Combined With Pioglitazone and Metformin Hydrochloride Tablets on Glucose and Lipid Metabolism and Islet Function in Patients With Type 2 Diabetes...” NCT07289750 ↗ “Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin...” NCT02503865 ↗ “Specifically, pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be used as an adjunct to agonist-based treatment.” NCT01395797 ↗ “The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy.” NCT02616666 ↗ “Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.” NCT01087567 ↗ “could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1).” NCT00481663 ↗ “Semaglutide 0.25 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd)” NCT06946628 ↗ “Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.” PMID 27560168 ↗ Aug 2016 “Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)” NCT06449235 ↗ “oral anti-diabetic agents (OADs: metformin, sulfonylureas, nateglinide, repaglinide or pioglitazone)” NCT01919489 ↗ “TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.” NCT00975286 ↗ “polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)” NCT00133718 ↗ “Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients” NCT06571591 ↗ “Metformin, Sulfonylureas, Sodium-glucose cotransporter-2 inhibitors, pioglitazone” NCT06243536 ↗ “Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg” NCT04584242 ↗ “thiazolidinediones (i.e. pioglitazone) enhance post-transplant islet function” NCT00214253 ↗ “Rosiglitazone was used by 74% and pioglitazone by 13% of participants.” PMID 26305617 ↗ Aug 2015 “Each patient will receive 30mg Pioglitazone daily for 24 months.” NCT01454336 ↗ “Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.” NCT02823808 ↗ “treatment with an insulin sensitizing drug (pioglitazone)” NCT00285844 ↗ “pioglitazone 30 mg tablet , once daily dose for 10 weeks” NCT01133561 ↗ “Tirzepatide, empagliflozin, and pioglitazone treatment.” NCT07635953 ↗ “Combination Pamapimod 75mg with Pioglitazone 5mg” NCT05659459 ↗ “Pioglitazone (thiazolidinedione) and vitamin-E” NCT07391267 ↗ “Actos (pioglitazone), Avandia (rosiglitazone)” NCT00396227 ↗ “Metformin (1000 mg) Pioglitazone (30 mg)” NCT03117517 ↗ “metformin, alogliptin and pioglitazone” NCT02683226 ↗ “sitagliptin 100mg, Pioglitazone 15mg” NCT06875193 ↗ “one arm pioglitazone (Actos®) 45mg” NCT00515632 ↗ “Vitamin E and/or Pioglitazone” NCT05813249 ↗ “Drug: pioglitazone 30mg” NCT01161394 ↗ “Pioglitazone (30 mg)” NCT04027023 ↗ “Pioglitazone therapy” NCT02888964 ↗ “pioglitazone (Actos)” NCT00000620 ↗ “Pioglitazone 30mg” NCT05411965 ↗ “pioglitazone” NCT00532935 ↗ “pioglitazone” NCT03720366 ↗ “Pioglitazone” NCT01894568 ↗ “pioglitazone” NCT04416269 ↗ |
| Known as | Actos | “The objective of this study was to investigate the bioequivalence of Mylan pioglitazone HCl 45 mg tablets to Takeda Actos® 45 mg tablets following a single, oral 45 mg (1 x 45...” NCT00649012 ↗32“This study will test whether pioglitazone hydrochloride (Actos (Registered Trademark) Registered Trademark) is effective for treating patients with asthma who do not respond to...” NCT00604578 ↗ “Patients who exhibit impaired glucose tolerance (IGT) after kidney transplantation are randomized to either receive vildagliptin (Galvus), pioglitazone(Actos) or placebo for...” NCT01346254 ↗ “the FDA-approved diabetes medication pioglitazone (Actos), which activates the gamma (g) subtype of peroxisome-proliferator-activated receptors (PPARs).” NCT01517165 ↗ “PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade \>1 related AE.” NCT02767063 ↗ “Pioglitazone hydrochloride (Actos ) is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-Gamma (PPAR Gamma).” NCT00994175 ↗ “This study will determine whether pioglitazone (Actos, a drug approved to treat diabetes, can benefit HIV-infected people with fatty liver.” NCT00441272 ↗ “the insulin-sensitizer pioglitazone (ActosTM, Takeda Pharma AG, Lachen, Switzerland) 15 mg QD” NCT00433069 ↗ “one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks” NCT01258322 ↗ “pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week” NCT02887625 ↗ “Palbociclib (PD-0332991); Pioglitazone (Actos)” NCT02222441 ↗ “Pioglitazone (Actos) 60 mg p.o. daily, day 1+” NCT01614301 ↗ “a PPAR- γ agonist (pioglitazone/Actos™)” NCT00315146 ↗ “PIO (Actos) is a thiazolidinedione” NCT06729996 ↗ “one arm pioglitazone (Actos®) 45mg” NCT00515632 ↗ “pioglitazone tablet (Actos®)” NCT02183636 ↗ “Drug: Pioglitazone (ACTOS®)” NCT05946564 ↗ “Pioglitazone 15 MG [Actos]” NCT06989723 ↗ “pioglitazone (Actos®)” NCT02888964 ↗ “Pioglitazone (Actos)” NCT00232362 ↗ “Actos® Tablets 45 mg” NCT00649558 ↗ “Pioglitazone (Actos)” NCT00926016 ↗ “ACTOS (Pioglitazone)” NCT00242177 ↗ “Actos (Pioglitazone)” NCT00062764 ↗ “Actos” NCT00395512 ↗ |
| Known as | Actos (brand name for pioglitazone) | “Actos (brand name for pioglitazone)” NCT00656864 ↗ |
| Known as | Actos (Takeda Pharmaceuticals). | “Actos (Takeda Pharmaceuticals).” NCT00227110 ↗ |
| Known as | Actos - pioglitazone | “Actos - pioglitazone” NCT00576784 ↗ |
| Known as | AD-4833 | “AD-4833-536 is a combination of AD-4833 (pioglitazone) and TAK-536 (azilsartan).” NCT01124656 ↗ |
| Known as | Diabiom | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Duetact | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Glidipion | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Glidipion (previously pioglitazone actavis group) | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Glizofar | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Glustin | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | NSC-758876 | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Paglitaz | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | PGZ | “A single center, open-label, fixed sequence study to evaluate the pharmacokinetics (PK) of Cenicriviroc (CVC) administered with and without Pioglitazone (PGZ), and to evaluate...” NCT02342067 ↗4“The peroxisome proliferator activated receptor-gamma agonist pioglitazone (PGZ suppresses vascular damage and immune dysregulation in murine lupus and improves endothelial...” PMID 35914929 ↗ Oct 2022 “a novel biomodulatory treatment regimen consisting of low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ) and all-trans retinoic acid (ATRA) induced...” PMID 30542286 ↗ Nov 2018 “Study objective is to determine whether Pioglitazone (PGZ) can improve clinical outcomes in hyperglycemic acute ischemic stroke (IS).” NCT04123067 ↗ “LSI + pioglitazone (PGZ) 15 mg qd” PMID 33397443 ↗ Jan 2021 |
| Known as | PIO | “The efficacy and safety of sitagliptin (SITA) monotherapy and
SITA/metformin (MET) vs. pioglitazone (PIO) were assessed in patients with type 2 diabetes and moderate-to-severe...” PMID 21849007 ↗ Sep 201112“Thiazolidinediones (TZDs), like pioglitazone (pio) or rosiglitazone, are a novel class of oral antidiabetic agents currently used to treat patients with type 2 diabetes mellitus.” NCT00376870 ↗ “This study aimed to investigate the complementary effects of combination therapy with pioglitazone (PIO) and empagliflozin (EMPA) on MASLD in individuals with type 2 diabetes.” PMID 40336058 ↗ May 2025 “Pioglitazone (PIO) is a peroxisome proliferator-activated receptor (PPAR)γ agonist insulin-sensitiser with anti-inflammatory and anti-atherosclerotic effects.” PMID 23811853 ↗ Jun 2013 “In addition to increasing insulin sensitivity, Pioglitazone (PIO) has anti-inflammatory properties.” NCT01040819 ↗ “who received 12 weeks of pioglitazone (PIO; 15 mg for 6 wk, then 30 mg daily) or matched placebo.” PMID 24937541 ↗ Jun 2014 “Pioglitazone (PIO) will be administered as a 15 mg oral dose per day for 5 days” NCT06164665 ↗ “the PPARγ agonist, pioglitazone (PIO) in increasing doses” NCT00827892 ↗ “Placebo / Teneli (Teneligliptin) + pio (pioglitazone)” NCT01026194 ↗ “Pioglitazone (PIO) + Clomiphene citrate” NCT07462065 ↗ “Pioglitazone (PIO)” NCT06729996 ↗ “Pioglitazone (PIO)” NCT07117630 ↗ “Pioglitazone (PIO)” NCT07180745 ↗ |
| Known as | Pioglar | “The complex therapy of the study group will include pioglitazone 15 mg 1 time per day in the morning ("Pioglar", Ranbaxy, India) for 6 months.” NCT03011775 ↗ |
| Known as | Pioglitazona | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone - Piosys, Pioglar | “Pioglitazone - Piosys, Pioglar” NCT00681733 ↗ |
| Known as | Pioglitazone accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone actavis | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone HCl | “A Phase 3b, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Pioglitazone HCl and Metformin HCl Fixed-Dose Combination Therapy Compared to Pioglitazone...” NCT00727857 ↗5“A Randomized, Double-blind, Double-dummy, Placebo-controlled 26-week Dose-response Study of Rivoglitazone HCl (CS-011) With Active Comparator (Pioglitazone HCl) in Subjects...” NCT00143520 ↗ “Pioglitazone HCl (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd. (Osaka, Japan).” NCT00655863 ↗ “Pioglitazone HCl Tablets 45 mg” NCT00649012 ↗ “Pioglitazone HCl Tablets 45 mg” NCT00649558 ↗ “pioglitazone HCl 15 mg” NCT00571519 ↗ |
| Known as | Pioglitazone hydrochlorid | “Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin...” NCT02503865 ↗ |
| Known as | pioglitazone hydrochloride | “After 24 weeks of Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment, the improvement of parameters estimated by MRI and liver fibroscan will...” NCT03950505 ↗15“Determine whether pioglitazone (pioglitazone hydrochloride) reverses leukoplakia in patients with hyperplastic or dysplastic oral cavity or oropharyngeal leukoplakia.” NCT00099021 ↗ “Pioglitazone hydrochloride (ACTOS®) is a member of a class of oral antidiabetic agents known as thiazolidinediones, which act by reducing insulin resistance.” NCT00727857 ↗ “The pioglitazone used by the alogliptin - pioglitazone combination therapy treatment group is pioglitazone hydrochloride and is a grey circular tablet.” NCT04470310 ↗ “Pioglitazone hydrochloride (Actos ) is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-Gamma (PPAR Gamma).” NCT00994175 ↗ “Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator- activated receptor-gamma agonist.” NCT00780234 ↗ “Pioglitazone hydrochloride, a thiazolidinedione compound, is a new therapeutic agent for the treatment of type 2 diabetes” NCT00991055 ↗ “single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion” NCT02473627 ↗ “The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months” NCT01589445 ↗ “ARM I: Patients receive pioglitazone hydrochloride orally (PO) once daily (QD) for 24 weeks.” NCT00951379 ↗ “Pioglitazone is a Pioglitazone hydrochloride, and white circle-shaped tablet.” NCT02426294 ↗ “Patients receive oral pioglitazone hydrochloride once daily on days 1-28.” NCT00867126 ↗ “pioglitazone hydrochloride. PO. 2 tablets once a day.” NCT05473806 ↗ |
| Known as | Pioglitazone hydrochloride component of actoplus met | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone hydrochloride component of duetact | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone hydrochloride component of oseni | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone krka | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone teva | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone teva pharma | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pioglitazone: Actos | “Pioglitazone: Actos®” NCT01318070 ↗4“pioglitazone (Actos)” NCT00000620 ↗ “Pioglitazone (Actos)” NCT01006018 ↗ “pioglitazone: actos” NCT00153166 ↗ “pioglitazone: ACTOS” NCT00953498 ↗ |
| Known as | Piomed | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Pionorm | “Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin...” NCT02503865 ↗ |
| Known as | Poze | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Sepioglin | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | STR-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | U-72107 | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | U-72107A | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Known as | Zactos | ChEMBL registry synonym — accepted as the source's own label CHEMBL595 ↗ |
| Action | Activate | “The mechanism of action is thought to be mediated by activation of peroxisome proliferator-activated receptors-gamma (PPAR-gamma).” NCT00013598 ↗ |
| Modality | Small molecule | “Pioglitazone is an antidiabetic drug that belongs to thiazolidinedione group.” NCT00013598 ↗ |
| Route | Oral | “patients start taking pioglitazone by mouth once a day for 48 weeks” NCT00013598 ↗ |
| Target | PPARG | “A Phase IIa Cancer Prevention Trial of the PPAR Gamma Agonist Pioglitazone in Oral Leukoplakia” NCT00099021 ↗ |